| Literature DB >> 21196649 |
Abdelmoneim Sulieman1, Georgios Paroutoglou, Andreas Kapsoritakis, Anargeyros Kapatenakis, Spiros Potamianos, Marianna Vlychou, Kiki Theodorou.
Abstract
BACKGROUND/AIM: Endoscopic retrograde cholangiopancreatography (ERCP) is associated with a considerable radiation exposure for patients and staff. While optimization of the radiation dose is recommended, few studies have been published. The purpose of this study has been to measure patient and staff radiation dose, to estimate the effective dose and radiation risk using digital fluoroscopic images. Entrance skin dose (ESD), organ and effective doses were estimated for patients and staff.Entities:
Mesh:
Year: 2011 PMID: 21196649 PMCID: PMC3099076 DOI: 10.4103/1319-3767.74456
Source DB: PubMed Journal: Saudi J Gastroenterol ISSN: 1319-3767 Impact factor: 2.485
ERCP indications
| Indications | Total | % |
|---|---|---|
| CBD stones | 29 | 50.9 |
| Post operation leakage | 3 | 5.2 |
| Cholangitis | 6 | 10.5 |
| Malignancy | 8 | 14.0 |
| Benign CBD stricture | 1 | 1.8 |
| Stent removal or exchange | 5 | 8.8 |
| Pancreatitis | 5 | 8.8 |
| Total | 57 | 100 |
ERCP: Endoscopic retrograde cholangiopancreatography, CBD: common bile duct
Figure 1Patient setup, lead apron and examiners positions during ERCP examination. 1. Gastroenterologist; 2. assistant gastroenterologist; M1., endoscopic monitor; M2. fluoroscopic monitor. T1 X ray tube. T2,Table, and L lead apron
Patient body characteristics (age, height, BMI and weight), screening time and number of radiographic and fl uoroscopic images. (mean and the range in the parentheses)
| Age group | n | Patient age (year) | Height (cm) | Weight (Kg) | BMI (Kg/m2) | Screening time (min) | No. of radiographic images | Procedure duration (min) |
|---|---|---|---|---|---|---|---|---|
| All | 57 | 65.8 (26-91) | 163.5 (149-186) | 74.6 (47-110) | 27.3 (17.9-42.9) | 2.9 (0.3-12.3) | 2.6 (1-6) | 27.5 (15-55) |
| Males | 32 | 64.9 (26-86) | 165.4 (149-186) | 74.9 (47-106) | 27.5 (17.9-40.6) | 2.6 (0.3-12.3) | 2.1 (1-5) | 25 (15-50) |
| Females | 25 | 65.8 (27-91) | 163.6 (150-185) | 74.6 (50-110) | 26.6 (18.6-42.9) | 3.2 (0.7-10) | 3.0 (1-6) | 30 (20-55) |
Minimum, median, mean, standard deviation (SD) third quartile and maximum values of ESD. The mean and range of TSD and patient radiation doses (mGy)
| Patient dose (mGy) | No. | Mean (±SD) | Minimum | Median | Third quartile | Maximum |
|---|---|---|---|---|---|---|
| ESD | 57 | 75.6±76 | 9.86 | 44.79 | 86.10 | 268.1 |
| Males | 32 | 73.9±68 | 10.17 | 36.77 | 83.49 | 268.1 |
| Females | 25 | 77.4±79 | 9.86 | 52.81 | 88.81 | 260.1 |
| Exit dose | 57 | 3.22±0.26 | 0.18 | 1.12 | 3.92 | 45.12 |
| Males | 32 | 2.33±0.23 | 0.19 | 1.14 | 4.36 | 45.12 |
| Females | 25 | 4.06±0.24 | 0.18 | 2.10 | 3.48 | 44.91 |
| TSD | 57 | 0.80±0.61 | 0.10 | 0.46 | 0.89 | 1.70 |
| Males | 32 | 0.55±0.53 | 0.06 | 0.34 | 0.74 | 1.56 |
| Females | 25 | 0.82±0.69 | 0.10 | 0.57 | 1.04 | 1.70 |
ESD: Entrance skin dose; TSD: Thyroid surface dose
Minimum, mean ± SD, median, third quartile and maximum values of staff radiation doses (µGy)
| Gastroenterologist | Mean ± SD | Minimum | Median | Third quartile | Maximum |
|---|---|---|---|---|---|
| Chest | 6.2±2.2 | 0.2 | 3.6 | 6.6 | 32.5 |
| Thyroid | 5.40±0.9 | 0.2 | 2.9 | 5.6 | 27.6 |
| Forehead | 3.81±2.1 | 0.2 | 2.4 | 6.6 | 26.3 |
| Hand | 27.2±46 | 1.02 | 13.8 | 53.1 | 223.2 |
| Effective dose (µSv) | 0. 4±1.7 | 0.01 | 0.3 | 0.5 | 11.8 |
| Chest | 0.5±1.8 | 3.3 | 2.03 | 3.3 | 17.3 |
| Hand | 0.2±1.6 | 6.6 | 3.1 | 11.6 | 32.5 |
| Effective dose (µSv) | 0.01±1.2 | 0.2 | 0.2 | 0.2 | 1.2 |
Mean organ radiation equivalent dose (mSv), risk coeffi cients and radiation risk per ERCP procedure
| Organ | Organ equivalent dose (mSv) | Nominal risk coeffi cient × 10-4Sv-1 | Radiationinduced cancer probability × 10-6 |
|---|---|---|---|
| Ovaries | 1.29 | 16 | 2 |
| Uterus | 1.42 | 6.3 | 1 |
| Breast | 0.28 | 116 | 3 |
| Skin | 1.91 | 670 | 128 |
| Hereditary effect | 1.29 | 20 | 3 |
| Effective dose | 3.44 | 550 | 190 |
Nominal risk in the whole population; ERCP: Endoscopic retrograde cholangiopancreatography
The mean patient parameters, screening time, number of radiographic images, ESD and effective dose in various therapeutic studies
| Author | n | Age (year) | BMI (Kg/m2) | Screening time (min) | No. of radiographic images | DAP Gy.cm2 | ESD (mGy) | Effective dose (mSv) |
|---|---|---|---|---|---|---|---|---|
| Sulieman | 57 | 66.8 (26-91) | 27.3 (17.9-42.9) | 2.9 (0.3-12.3) | 2.6 (1-6) | NR | 75.6 | 4.16 |
| Larkin | 12 | 74.8 (60-89) | NR | 10.5 (5.9-16.6) | 3.7 | 66.8 | NR | 12.4 |
| Tsalafoutas | 21 | 66 (34-92) | NR | 6 (1.3-23.5) | 2.9 (2-4) | 41.8 | 178.9 | 8.7 |
| Heyd | 72 | 53.6 (20.6-86.5) | 26.11 (17.5-61) | 14 (2-63) | 16 (6-45) | NR | 80 | NR |
| Chen | 12 | 60 (22-89) | NR | 5.9 | 4 | NR | 262 | NR |
| Buls | 54 | 66.5 (41.5-81) | NR | 6 | 4 | 49.9 | 347 | 9.9 |
NR: not reported, ESD: Entrance skin dose; DAP: Dose area product,
Diagnostic procedures, Range is in parenthesis
Figure 2(a) A comparison of ESD and effective dose for ERCP patients with those published, previously. (b) A comparison of thyroid and eye lens doses for staff with previous studies